Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
23.67
-0.03 (-0.13%)
Feb 21, 2025, 4:00 PM EST - Market closed
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Dianthus Therapeutics stock have an average target of 46.43, with a low estimate of 36 and a high estimate of 58. The average target predicts an increase of 96.16% from the current stock price of 23.67.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +68.99% | Nov 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $48 → $52 | Buy | Maintains | $48 → $52 | +119.69% | Nov 11, 2024 |
| Raymond James | Raymond James | Buy Maintains $51 → $56 | Buy | Maintains | $51 → $56 | +136.59% | Nov 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $48 | Buy | Initiates | $48 | +102.79% | Oct 3, 2024 |
Financial Forecast
Revenue This Year
5.66M
from 2.83M
Increased by 100.14%
Revenue Next Year
3.79M
from 5.66M
Decreased by -33.08%
EPS This Year
-2.61
from -8.45
EPS Next Year
-3.52
from -2.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.4M | 9.1M | 9.1M | ||
| Avg | 5.7M | 3.8M | 3.7M | ||
| Low | 2.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 163.1% | 61.3% | 141.0% | ||
| Avg | 100.1% | -33.1% | -3.2% | ||
| Low | -6.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.88 | -2.43 | -2.84 | ||
| Avg | -2.61 | -3.52 | -3.90 | ||
| Low | -3.00 | -4.38 | -4.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.